Replies to post #222975 on Biotech Values

[DewDiligence]

BMY/CELG—FDA approves Reblozyl (luspatercept) for beta thalassemia:

https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treat-patients-rare-blood-disorder

This is not one of three drug approvals that comprise the CELG CVR—those are detailed in #msg-145844551.